Browse News
Filter News
Found 92 articles
-
Long Read Sequencing Market to reach US$ 5,334.68 million by 2028 COVID-19 Impact and Global Analysis By Technology Application and Geography By The Insight Partners
6/24/2021
Factors such as the advantages of long read sequencing and increasing prevalence of chronic diseases fuel the growth of the long read sequencing market.
-
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
-
Artificial, Inc. Expands Leadership Team and Board of Directors to Catalyze the Lab’s Digital Revolution
1/19/2021
Artificial, a lab automation company that is catalyzing the life science digital revolution with its first-of-its-kind orchestration platform, announced the addition of Dr. Yvonne Linney to its Board of Directors and executive leadership team as Chief Operating Officer (COO).
-
HistoGenetics Expands Service Offerings and Capacity to Deliver More Complete Genomic Information
11/17/2020
With optical mapping, long-read sequencing, single-cell analysis, and other advanced genomic technologies, HistoGenetics supports projects for clinical, translational, and research applications
-
Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer
10/8/2020
Kristiina Vuori, M.D., Ph.D. is a leading genetics and cancer researcher who serves as President and Board member of Sanford Burnham Prebys Medical Discovery Institute
-
When Bionano Genomics acquired Lineagen, Inc. in August, the genomic analysis company gained the final piece it needed to provide comprehensive structural variation detection for researchers and drug developers and a reimbursement pathway for clinicians who want to use its technology to replace c...
-
BioSpace Movers & Shakers, Aug. 21
8/21/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Turning Point Therapeutics Names Heather Adams as Vice President of Human Resources
7/27/2020
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Heather Adams as vice president of Human Resources, effective today. Ms. Adams has more than 20 years of human resources experience, primarily in the health care industry across multiple biotechnology and medical device companies. “As we grow the company, Heathe
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
-
Rescale Partners with Google Cloud and Microsoft Azure to Accelerate the Race for COVID-19 Vaccine with Cloud Supercomputers for Researchers
3/19/2020
High performance computing resources immediately available at no cost to engineers, scientists, and researchers fighting the novel coronavirus
-
Breakthrough Findings in Leukemias Presented at ASH 2019 Demonstrate Bionano Saphyr's Potential to Replace All Cytogenetic Methods and Show Additional Clinical Utility
12/5/2019
Bionano’s new DNA Isolation Kit for Bone Marrow Aspirates enables routine clinical analysis of Leukemia samples.
-
Takeaways from AMP 2019 in Baltimore: Users of Bionano's Saphyr System Presented Results from Multiple Studies Demonstrating the System's Utility for a Variety of Disease Indications
11/12/2019
Saphyr provides a platform that streamlines traditional workflows and provides a path to solving previously intractable scientific questions connected to the mechanisms of disease
-
Bionano Genomics Reports Third Quarter 2019 Financial Results and Provides Business Update
11/7/2019
Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its financial results for the third quarter and nine months ended September 30, 2019 and provided a business update.
-
Novogene Adopts Bionano's Saphyr System Adding Saphyr's Ultra-Sensitive and Ultra-Specific Structural Variation Detection to their Repertoire of Services
11/6/2019
Novogene’s global customers will now have a high-throughput solution for long-read genome analysis enabling clinical-grade structural variation discovery and platinum genome assembly
-
Bionano Genomics to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 7
11/4/2019
Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that it will host a conference call and live webcast on Thursday, November 7, 2019 at 4:30 pm Eastern Time to report financial results for its third quarter ended September 30, 2019 and provide a business update.
-
Takeaways from ASHG 2019 in Houston: Users of Bionano's Saphyr System Presented Validation Results for FSHD, Repeat Expansion Disorders and Digital Cytogenetics Among a Growing List of Applications of Saphyr in Human Genetics and Cancer Research
10/24/2019
Saphyr provides a platform that streamlines traditional workflows and provides a path to solving previously intractable scientific questions connected to the mechanisms of disease
-
Bionano Genomics Announces Pricing of $18 Million Underwritten Public Offering
10/21/2019
Bionano Genomics, INC. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced the pricing of an underwritten public offering.
-
Bionano Genomics Announces Adoption of Its Saphyr® System by Clinical Cytogenetics Groups in Academia and Industry to Replace Traditional Methods for Clinical Testing
10/16/2019
Successful validation of Saphyr to replace “gold standard” method of southern blotting for molecular diagnosis of FSHD supports broad utility of Saphyr